imiglucerase (Sanofi)
86
Structured Review
Sanofi
imiglucerase
Imiglucerase, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cerezyme/imiglucerase/pm41821052-41-26-28
Average 86 stars, based on 1 article reviews
Imiglucerase, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cerezyme/imiglucerase/pm41821052-41-26-28
Average 86 stars, based on 1 article reviews
imiglucerase - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Recombinant:Article Title: A Common PD-Risk GBA1 Variant Disrupts LIMP2 Interaction, Impairs Glucocerebrosidase Function, and Drives Lysosomal and Mitochondrial Dysfunction Article Snippet: .. The GCase reactions were initiated by the addition of executed commercially available other:Article Title: 10-K Article Snippet: The most commonly prescribed ERTs for Gaucher disease are Article Title: Use of Identical INN “Imiglucerase” for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database Article Snippet: IAR infusion-associated reactions Fig. 2 a Most frequent (three or more) adverse events reported among Cerezyme cases. b Most frequent (three or more) adverse events reported among Asbroder cases During the post-Asbroder approval reporting period (11 October, 2015 to 1 March, 2018), 132 cases with 333 AEs were reported in patients while receiving imiglucerase therapy to the Generated:Article Title: 10-K Article Snippet: .. In 2022, Sanofi’s Clinical Proteomics:Article Title: Current state of the art in treatment of Mendelian disease: Skeletal dysplasias. Article Snippet: Funding information Greenberg Center for Skeletal Dysplasias Abstract The current state of the art in treatment of Mendelian disease, specifically skeletal dysplasias, benefits tremendously from Dr. Victor McKusick's early delineation and standardization of the nomenclature surrounding these conditions.. Through close observation and careful description of each dysplasia to flesh out the nosologic backbone of the genetic skeletal disorders, individuals with the same diagnosis were identified and grouped together for genetic interrogation.. These efforts have resulted in the identification of the genetic etiology of nearly all recognized skeletal disorders. |